Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
ID: ALA4797451
Max Phase: Preclinical
Molecular Formula: C62H86F2N10O10
Molecular Weight: 1169.43
Molecule Type: Unknown
Associated Items:
ID: ALA4797451
Max Phase: Preclinical
Molecular Formula: C62H86F2N10O10
Molecular Weight: 1169.43
Molecule Type: Unknown
Associated Items:
Canonical SMILES: Cc1nnc(C(C)C)n1[C@H]1C[C@H]2CC[C@@H](C1)N2CC[C@H](NC(=O)C1CCC(F)(F)CC1)c1ccc(NC(=O)COCC(=O)NCCCCCNC(=O)COCC(=O)N[C@@H]2CC[C@@]3(O)[C@H]4Cc5ccc(O)c6c5[C@@]3(CCN4CC3CC3)[C@H]2O6)cc1
Standard InChI: InChI=1S/C62H86F2N10O10/c1-37(2)58-71-70-38(3)74(58)46-30-44-14-15-45(31-46)73(44)27-20-47(69-59(80)41-17-21-60(63,64)22-18-41)40-9-12-43(13-10-40)67-53(78)35-82-33-51(76)65-25-5-4-6-26-66-52(77)34-83-36-54(79)68-48-19-23-62(81)50-29-42-11-16-49(75)56-55(42)61(62,57(48)84-56)24-28-72(50)32-39-7-8-39/h9-13,16,37,39,41,44-48,50,57,75,81H,4-8,14-15,17-36H2,1-3H3,(H,65,76)(H,66,77)(H,67,78)(H,68,79)(H,69,80)/t44-,45+,46+,47-,48+,50+,57-,61-,62+/m0/s1
Standard InChI Key: JIYSTYUGXTVTHE-SSNNPUIESA-N
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Natural Product: No | Oral: No | Chemical Probe: No | Parenteral: No |
Molecule Type: Unknown | Topical: No | First In Class: No | Black Box: No |
Chirality: No | Availability: No | Prodrug: No |
MESH ID | MESH Heading | EFO IDs | EFO Terms | Max Phase for Indication | References |
---|
Mechanism of Action | Action Type | target ID | Target Name | Target Type | Target Organism | Binding Site Name | References |
---|
Molecular Weight: 1169.43 | Molecular Weight (Monoisotopic): 1168.6496 | AlogP: | #Rotatable Bonds: |
Polar Surface Area: | Molecular Species: | HBA: | HBD: |
#RO5 Violations: | HBA (Lipinski): | HBD (Lipinski): | #RO5 Violations (Lipinski): |
CX Acidic pKa: | CX Basic pKa: | CX LogP: | CX LogD: |
Aromatic Rings: | Heavy Atoms: | QED Weighted: | Np Likeness Score: |
1. Arnatt CK,Falls BA,Yuan Y,Raborg TJ,Masvekar RR,El-Hage N,Selley DE,Nicola AV,Knapp PE,Hauser KF,Zhang Y. (2016) Exploration of bivalent ligands targeting putative mu opioid receptor and chemokine receptor CCR5 dimerization., 24 (22.0): [PMID:27720326] [10.1016/j.bmc.2016.09.059] |
Source(1):